Tejara Capital Ltd Grows Stake in OPKO Health, Inc. (NASDAQ:OPK)

Tejara Capital Ltd raised its stake in OPKO Health, Inc. (NASDAQ:OPK) by 11.3% during the fourth quarter, Holdings Channel reports. The fund owned 1,225,650 shares of the biotechnology company’s stock after buying an additional 124,524 shares during the period. OPKO Health makes up approximately 1.2% of Tejara Capital Ltd’s portfolio, making the stock its 24th largest position. Tejara Capital Ltd’s holdings in OPKO Health were worth $1,802,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in OPK. FMR LLC raised its position in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares during the period. Orion Portfolio Solutions LLC bought a new stake in shares of OPKO Health in the third quarter valued at approximately $45,000. Cibc World Markets Corp bought a new stake in shares of OPKO Health in the fourth quarter valued at approximately $45,000. Ieq Capital LLC bought a new stake in shares of OPKO Health in the fourth quarter valued at approximately $52,000. Finally, World Investment Advisors LLC bought a new stake in shares of OPKO Health in the third quarter valued at approximately $61,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on OPK shares. Barrington Research reissued an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Wednesday, March 12th. Finally, StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost purchased 500,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were purchased at an average price of $1.48 per share, with a total value of $740,000.00. Following the acquisition, the chief executive officer now directly owns 213,036,477 shares of the company’s stock, valued at approximately $315,293,985.96. This represents a 0.24 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased 964,971 shares of company stock valued at $1,493,692 in the last quarter. Insiders own 47.26% of the company’s stock.

OPKO Health Stock Performance

OPKO Health stock opened at $1.81 on Tuesday. The firm’s 50 day simple moving average is $1.63 and its 200 day simple moving average is $1.57. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $1.22 billion, a PE ratio of -9.53 and a beta of 1.70. OPKO Health, Inc. has a 1-year low of $0.86 and a 1-year high of $2.04.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.